Slide 1: Investor Presentation
Investor Presentation April 28, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2026 guidance, strategic and growth opportunities, other expectations and other non-historical informa
Slide 3: Our Purpose and Guiding Principles
Investor Presentation – April 28, 2026 Our Purpose Our Guiding Principles To be the healthcare Our Guiding Principles represent what we providers’ most trusted stand for as a company, guiding us in every partner to enable the aspect of how we do business. Autonomous Pharmacy transformation o Passion
Slide 4: Omnicell Investment Highlights
Investor Presentation – April 28, 2026 Omnicell Investment Highlights A recognized leader in medication management with a 30-year track record and an installed base that includes more than one-half of the top 300 U.S. health systems* With Omnicell Titan XT, powered by our OmniSphere platform, Omnice
Slide 5: Omnicell's Growth Strategy
Investor Presentation – April 28, 2026 Omnicell’s Growth Strategy is to: CONNECT the health network DISRUPT pharmacy care with innovation GROW where care is being delivered © 2026 Omnicell, Inc. 5
Slide 6: Our Strategy
Investor Presentation – April 28, 2026 Our Strategy Omnicell is focused on delivering autonomous medication management solutions designed to help healthcare facilities worldwide to improve efficiency and enhance patient safety across all settings of care. HEALTH SYSTEM OUTPATIENT Central Pharmacy/ P
Slide 7: The Autonomous Pharmacy
Investor Presentation – April 28, 2026 The Autonomous Pharmacy Industry-Defined Vision Replace manual, error-prone activities with automated processes that are designed to be safer and more efficient. o Zero medication errors o Zero medication waste o Zero human touches until delivery to patient o 1
Slide 8: Delivering Solutions Designed to Support Customer Operational and Economic Environments
Investor Presentation – April 28, 2026 Delivering Solutions Designed to Support Customer Operational and Economic Environments CHALLENGE OUTCOME DELIVERED Barcode scanning through Central 25,000 Errors Annually in Hospitals 1 100% Pharmacy robotics supports enhanced safety and accuracy 5 $4.5B Net l
Slide 9: Revenue Growth Drivers
Investor Presentation – April 28, 2026 Revenue Growth Drivers Deep Customer Relationships and Multiple Growth Robust Product Backlog and Annual Drivers Recurring Revenue o Strong position with more than one- o Expanding Our Market Presence half of the top 300 U.S. health Expanding our footprint with
Slide 10: Why We Believe Omnicell is Positioned to Win
Investor Presentation – April 28, 2026 Why We Believe Omnicell is Positioned to Win Omnicell has the right Omnicell has a proven Omnicell is scaling SaaS Continued investment in solutions and the right track record of innovation and Expert Services to new products and business model to solve as the
Slide 11: Omnicell Innovation
Omnnicell Innovation . @ ()
Slide 12: Introducing Titan XT on OmniSphere
Investor Presentation – April 28, 2026 Introducing Titan XT on OmniSphere Built for the modern needs of Health Systems Omnicell Titan XT Automated Dispensing System (ADS) is engineered to streamline pharmacy workflows, enhance nursing safeguards, and simplify IT operations through intelligent, enter
Slide 13: Titan XT – Reimagined Smart Workflows
Investor Presentation – April 28, 2026 Titan XT – Reimagined Smart Workflows Cabinet interactions are streamlined through user-specific guided workflows, which should enable staff to focus on high-priority tasks with greater efficiency and reduced cognitive load. Automated Workflows should remove th
Slide 14: Omnicell Titan XT – Focused on Improving Outcomes and User Experience
Investor Presentation – April 28, 2026 Omnicell Titan XT – Focused on Improving Outcomes and User Experience FiveRights DynamicRestock Intended to ensure the five rights of medication Give technicians clear task visibility and managers administration are easy for nurses with specific prompts real-ti
Slide 15: Powered by OmniSphere
Investor Presentation – April 28, 2026 Powered by OmniSphere Safe with leading security and compliance standards As Omnicell’s secure cloud platform, OmniSphere is designed to be the connected backbone of medication Smart management, providing scalability, decisions with broad one source of truth, i
Slide 16: Product Overview
Product Overview
Slide 17: Points of Care
Investor Presentation – April 28, 2026 Points of Care As the final step in the pharmaceutical administration process, the bedside exchange of medication from nurse to patient is critical to care success. However, countbacks, restocks, reconciliation, and other manual tasks may force nurses to spend
Slide 18: Central Pharmacy
Investor Presentation – April 28, 2026 Central Pharmacy Central pharmacy is the medication dispensing hub of most hospitals. Roadblocks that surface here have the potential to impact patient safety, care, and clinical workflows throughout the health system. Omnicell automates manual dispensing tasks
Slide 19: IV Room
Investor Presentation – April 28, 2026 IV Room Accuracy and sterility in IV compounding are paramount to patient safety, but an overreliance on 503B outsourcing and manual in-house systems often creates unnecessary risk and expense. Omnicell’s advanced automation tools including sterile compounding
Slide 20: Specialty Pharmacy
Investor Presentation – April 28, 2026 Specialty Pharmacy As medical innovations create new, more complex drugs, many pharmacies need specialized tools and expertise to help manage the patient’s treatment journey. Opening or optimizing an in-house specialty pharmacy often requires unique capabilitie
Slide 21: EnlivenHealth
Investor Presentation – April 28, 2026 EnlivenHealth® Optimizing a patient’s medication journey often means extending care beyond the inpatient setting and enhancing the processes of retail and community pharmacies. Through EnlivenHealth®, Omnicell provides patient engagement software and omnichanne
Slide 22: Medication Adherence
Investor Presentation – April 28, 2026 Medication Adherence Through industry-leading packaging and automation solutions, Omnicell Medication Adherence helps to empower pharmacies to work more efficiently as they seek to and improve medication safety and effectiveness for customers and patients. Pack
Slide 23: Omnicell's Suite of SaaS and Expert Services
Investor Presentation – April 28, 2026 Omnicell’s Suite of SaaS and Expert Services Varying combinations of robotics and smart devices, software workflows, expert services, and analytics that are designed to deliver outcomes in each setting of care where medications are managed Points of Care Centra
Slide 24: First Quarter 2026 Financial Highlights
First Quarter 2026 Financial Highlights
Slide 25: Financial Snapshot
Investor Presentation – April 28, 2026 Financial Snapshot Q1 ’26 YoY Change Total Revenues $310 million 15% Non-GAAP Gross Margin % 45.9% 380 bps Non-GAAP Operating Expenses $111 million 6% Non-GAAP EBITDA $45 million 89% Non-GAAP Diluted Earnings Per Share $0.55 112% See Appendix for a reconciliati
Slide 26: Total Year Revenue Composition
Investor Presentation – April 28, 2026 Total Year Revenue Composition TY 2026 YoY Recurring vs Guidance GAAP ($Million) Category Actual 1Q26 Change % Non Recurring TY–2026 (Mid-Point) 1 Connected Devices and Software Licenses Non Recurring Product $149 $690–$710 5% Consumables Recurring Product $26
Slide 27: 2026 Guidance
Investor Presentation – April 28, 2026 Long-Term Value Creation 2026 Guidance Opportunities Q2–2026 TY–2026 o Leadership position in the digital transformation of healthcare Product bookings Not guided $510–$560 million o Omnicell’s Titan XT is designed to combine proven automation and ARR Not guide
Slide 28: An Outcomes-Based Approach to ESG
2024 Investor Presentation – April 28, 2026 An Outcomes-Based Approach to ESG ESG Report Environmental Published fifth annual o Continued our efforts to reduce our environmental footprint and energy consumption, realizing decreases in both ESG Report in April 2025 emissions and energy use o Complete
Slide 29: Appendix
Appendix
Slide 30: Omnicell, Inc. Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP audited, in thousands, except per share data and percentage) Three Months Ended March 31, Reconciliation of GAAP gross profit to non-GAAP gross profit: GAAP gross profit GAAP gross margin Share-based compensation expense Amortization of acquired inta
Slide 31: Reconciliation footnote: tax effects
© 2026 Omnicell, Inc. (a) Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2025 and 2024. 31
Slide 32: Reconciliation footnote: EBITDA definition
© 2026 Omnicell, Inc. (b) Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. 32
Slide 33: Slide 33